Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)
The article presents epidemiological data on the high prevalence of hypertension and dyslipidemia comorbidity in the general population, as well as shows the leading role of these key cardiovascular risk factors in the development of cardiovascular events. At the same time, within the primary preven...
Saved in:
| Main Author: | V. V. Kashtalap |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/5285 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hypertension and Hypercholesterolemia: is it Time for Anti-«Lipitensive» Therapy?
by: Z. D. Kobalava, et al.
Published: (2020-11-01) -
Increment of the effectiveness of treating hypertension and dyslipidemia using a triple fixed-dose combination and the vascular age concept
by: O. V. Tsygankova, et al.
Published: (2020-09-01) -
Association of Unhealthy Lifestyle Score on the Risk of Hypertension, Dyslipidemia, and Their Comorbidity in Korea: A Cross-Sectional Study
by: Ji-Sook Kong, et al.
Published: (2024-02-01) -
TREATMENT OF ARTERIAL HYPERTENSION AND DYSLIPIDEMIA IN REAL CLINICAL PRACTICE. THE SYNERGY STUDY. Part 2
by: O. M. Drapkina, et al.
Published: (2017-07-01) -
Intensification of lipid-lowering therapy in very high-risk patients: potential of combination with PCSK9 inhibitors
by: D. Yu. Sedykh, et al.
Published: (2022-07-01)